

Claudia Kedor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2089388/publications.pdf>

Version: 2024-02-01

16
papers

410
citations

1162367

8
h-index

996533

15
g-index

19
all docs

19
docs citations

19
times ranked

312
citing authors

#	ARTICLE	IF	CITATIONS
1	Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). <i>Journal of Translational Medicine</i> , 2022, 20, 138.	1.8	116
2	Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1090-1097.	0.5	56
3	Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3675.	1.0	38
4	Hand grip strength and fatigability: correlation with clinical parameters and diagnostic suitability in ME/CFS. <i>Journal of Translational Medicine</i> , 2021, 19, 159.	1.8	31
5	SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity. <i>Frontiers in Immunology</i> , 2022, 13, 840126.	2.2	20
6	Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study—a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. <i>RMD Open</i> , 2021, 7, e001660.	1.8	19
7	A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome. <i>Clinical Rheumatology</i> , 2016, 35, 2203-2210.	1.0	15
8	Delineating the Association Between Soluble CD26 and Autoantibodies Against G-Protein Coupled Receptors, Immunological and Cardiovascular Parameters Identifies Distinct Patterns in Post-Infectious vs. Non-Infection-Triggered Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 644548.	2.2	14
9	Update on the therapy of adult-onset Still's disease with a focus on IL-1-inhibition: a systematic review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110595.	1.2	10
10	Distinct Effects of Interleukin-1 β Inhibition upon Cytokine Profile in Patients with Adult-Onset Still's Disease and Active Articular Manifestation Responding to Canakinumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 4400.	1.0	6
11	Response to: "Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still's disease" by Ruscitti et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e104-e104.	0.5	4
12	Response to abatacept is associated with the inhibition of proteasome β 1i expression in T cells of patients with rheumatoid arthritis. <i>RMD Open</i> , 2020, 6, e001248.	1.8	3
13	Response to: "Correspondence on "Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease" by Muraviov and Muraviova. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e234-e234.	0.5	3
14	Diagnostic accuracy of dual-energy computed tomography and joint aspiration: a prospective study in patients with suspected gouty arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 1061-1067.	0.4	3
15	THU0561...CANAKINUMAB FOR THE TREATMENT OF ADULT ONSET STILL'S DISEASE TO ACHIEVE REDUCTION OF ARTHRITIC MANIFESTATION AT WEEK 12: AN INVESTIGATOR-INITIATED MULTI-CENTRE, PLACEBO-CONTROLLED STUDY (CONSIDER). , 2019, , .		1
16	Canakinumab for Treatment of Adult Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): A Phase 2, Multi-Centre, Placebo-Controlled Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1